-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since 2012, (targeted) therapy strategies for HER2-positive early breast cancer have been greatly optimized
breast cancer
The WSG-ADAPT-HER2+/HR- trial was an investigator-initiated, multicenter, open-label, randomized Phase 2 study recruiting 18 years of age and older, histologically confirmed, unilateral, primary invasive, Patients with hormone receptor-negative and HER2-positive, non-inflammatory early breast cancer were randomized (5:2) to receive trastuzumab (8 mg/kg for the first dose, followed by 6 mg/kg for 3 weeks) + Pertuzumab (the first dose of 840 mg/kg, followed by 420 mg/kg for 3 weeks) or trastuzumab + pertuzumab + paclitaxel (80 mg/m2 weekly)
Between March 3, 2014, and October 6, 2015, a total of 134 patients were recruited and randomly divided into two groups: 92 in the duplex group and 42 in the triplet group
There were no significant differences in invasive disease-free survival, recurrence-free survival, local recurrence-free survival, distant disease-free survival, and overall survival between treatment groups
98 87 Pathological complete response rates are associated with improved invasive disease-free survival rates Pathological complete response rates are associated with improved invasive disease-free survival rates
In conclusion, the results of this study showed that patients who achieved pathological complete remission after 12 weeks of trastuzumab + pertuzumab ± paclitaxel achieved good survival
Patients who achieved pathological complete remission after 12 weeks of trastuzumab + pertuzumab ± paclitaxel had good survival rates
Original source:
Original source:Nitz Ulrike,Gluz Oleg,Graeser Monika et al.
Nitz Ulrike,Gluz Oleg,Graeser Monika et al.
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
[J] .
Lancet Oncol, 2022, https://doi.
org/10.
1016/S1470-2045(22)00159-0
Leave a comment here
